GlaxoSmithKline
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, GlaxoSmithKline sits in the top decile of US sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count).
GlaxoSmithKline: 1,345 sponsored US clinical trials, 50 recruiting.
GlaxoSmithKline sponsors 1,345 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 1,130 completed. 486 of these trials are in Phase 3-4 (later-stage) and 791 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 30 trials.
Top-decile sponsor footprint
GlaxoSmithKline ranks in the top decile of sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,249 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,345 total, page 17 of 27
DDI Study of Etravirine and GSK1265744
NCT00920296
Treatment With Pazopanib for Neoadjuvant Breast Cancer
NCT00849472
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
NCT00942136
A Pharmacokinetic Study of an Experimental Paracetamol Formulation
NCT01476176
Paracetamol With Caffeine to Treat Episodic Tension Type Headache
NCT01755702
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
NCT00920257
Study to Test GSK256073 in Patients With Dyslipidemia
NCT00903617
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
NCT01119846
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
NCT00880321
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
NCT00861744
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
NCT00920088
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
NCT00903422
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
NCT00875446
Thiazolidinedione Intervention With Vitamin D Evaluation
NCT00879970
Relative Bioavailability Study in Healthy Subjects
NCT00924911
Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States
NCT00875641
ARI103094-Follow-Up Study for REDUCE Study Subjects
NCT00883909
GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir
NCT00883935
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years
NCT00871117
Tafenoquine/Chloroquine DDI Study
NCT00871156
VEG111485: A QTc Study of Pazopanib
NCT00861029
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
NCT00880048
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
NCT00849329
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
NCT00821054
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
NCT00811733
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
NCT00880399
A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00857766
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
NCT00835237
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838903
Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting
NCT01013948
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916
The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity
NCT01587950
GSK1349572 Mass Balance Study
NCT00828763
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
NCT00790907
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
NCT00833378
A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects
NCT00823940
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
NCT00802464
Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride
NCT01563172
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
NCT00799825
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056
A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572
NCT00858455
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
NCT00843193
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
NCT00799903
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
NCT00812929
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
NCT00796445
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
NCT00791518
Migraine Study in Adolescent Patients
NCT00843024
A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations
NCT01568749
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 440 |
| Phase 2 | 351 |
| Phase 3 | 377 |
| Phase 4 | 109 |
Therapeutic Areas
What is open in the GlaxoSmithKline pipeline
50 recruiting of 1,345 indexed (4% open); 1,130 completed (84%).
Phase mix: 486 late (III/IV) vs 791 early (I/II) (early-phase heavy).
Top condition: Pulmonary Disease, Chronic Obstructive (30 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GlaxoSmithKline: open-pipeline peers nationwide
Peers matched on 1,345 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,345 trials (± recruiting share)
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Stryker Orthopaedics · 4% recruiting · 27 trials
- US Oncology Research · 4% recruiting · 27 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this GlaxoSmithKline page
1,345 registered trials is a research-attention snapshot, not an endorsement of GlaxoSmithKline or any single study.
- 50 of GlaxoSmithKline's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Disease, Chronic Obstructive is the condition GlaxoSmithKline studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GlaxoSmithKline pipeline card: 1,345 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.